We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The company posted adjusted earnings per share (EPS) of $3.29 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 10%. Align Technology beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.
ALGN’s Q1 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.02 billion, which suggests 4.3% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.26 per share, which implies a 6.1% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q1 Earnings
Estimates for first-quarter earnings have remained unchanged at $2.26 per share in the past 30 days.
Here’s a brief overview of the company’s performance leading up to this announcement.
Factors Shaping ALGN’s Q1 Performance
Clear Aligner
The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, Latin America and APAC, with stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids.
Align Technology’s fourth quarter marked a new all-time high for the number of doctors submitting Invisalign case starts. This might have extended into the first quarter as well. Dental and orthodontic service organizations (DSOs) remain a key, scalable growth channel in the reported quarter, with continued strong progress across all major regions.
In China, the rollout of volume-based procurement (VBP) is facing delays and is likely to begin in public hospitals before broader adoption. Despite uncertainty around timing and scope, the company is well positioned to manage potential pricing changes. From a product standpoint, it is likely to have seen strong contributions from Invisalign First and the Invisalign Palatal Expander with Mandibular Advancement with Occlusal Blocks.
The Zacks Consensus Estimate for Clear Aligner revenues indicates 4.8% year-over-year growth.
Imaging Systems & CAD/CAM Services (Systems and Services)
Within this segment, revenues are likely to have benefited from higher volumes across all regions and continued adoption of iTero Lumina scanner. With iTero Lumina accounting for more than 86% of Align Technology’s full system units in the fourth quarter, adoption and utilization are likely to have continued through wand upgrades and installations of new full systems.
exocad achieved strong revenue growth and is piloting exocad ART in select European markets, with broader rollout planned this year. Its strong lab presence enhances integration with iTero scanner and Invisalign. We expect this trend to have persisted in the first quarter as well.
The company’s growing suite of digital diagnostic tools, including Align Oral Health Suite and Align X-ray Insights, helps doctors identify conditions earlier and deliver clearer, more informed treatment recommendations. We expect all these tools to have positively impacted Align Technology’s revenues in the first quarter.
The Zacks Consensus Estimate for the segment’s revenues implies an increase of 2.3% on a year-over-year basis.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:
Earnings ESP: Align Technology has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1 at present. The company is expected to release first-quarter 2026 results soon.
AGEN’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 31.42%. The Zacks Consensus Estimate for first-quarter EPS implies an increase of 289.3% from the year-ago quarter’s figure.
Biogen (BIIB - Free Report) has an Earnings ESP of +3.26% and a Zacks Rank #2 at present. The company is slated to release first-quarter 2026 results soon.
BIIB’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 19.8%. The Zacks Consensus Estimate for first-quarter EPS implies a year-over-year decrease of 0.3%.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2 at present. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for first-quarter EPS suggests a 17.7% year-over-year improvement.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Align Technology's Q1 Earnings on Deck: Here's What to Expect
Key Takeaways
Align Technology, Inc. (ALGN - Free Report) is set to release first-quarter 2026 results on April 29, after the closing bell.
The company posted adjusted earnings per share (EPS) of $3.29 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 10%. Align Technology beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.
ALGN’s Q1 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.02 billion, which suggests 4.3% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.26 per share, which implies a 6.1% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q1 Earnings
Estimates for first-quarter earnings have remained unchanged at $2.26 per share in the past 30 days.
Here’s a brief overview of the company’s performance leading up to this announcement.
Factors Shaping ALGN’s Q1 Performance
Clear Aligner
The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, Latin America and APAC, with stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids.
Align Technology’s fourth quarter marked a new all-time high for the number of doctors submitting Invisalign case starts. This might have extended into the first quarter as well. Dental and orthodontic service organizations (DSOs) remain a key, scalable growth channel in the reported quarter, with continued strong progress across all major regions.
In China, the rollout of volume-based procurement (VBP) is facing delays and is likely to begin in public hospitals before broader adoption. Despite uncertainty around timing and scope, the company is well positioned to manage potential pricing changes. From a product standpoint, it is likely to have seen strong contributions from Invisalign First and the Invisalign Palatal Expander with Mandibular Advancement with Occlusal Blocks.
The Zacks Consensus Estimate for Clear Aligner revenues indicates 4.8% year-over-year growth.
Align Technology, Inc. Price and EPS Surprise
Align Technology, Inc. price-eps-surprise | Align Technology, Inc. Quote
Imaging Systems & CAD/CAM Services (Systems and Services)
Within this segment, revenues are likely to have benefited from higher volumes across all regions and continued adoption of iTero Lumina scanner. With iTero Lumina accounting for more than 86% of Align Technology’s full system units in the fourth quarter, adoption and utilization are likely to have continued through wand upgrades and installations of new full systems.
exocad achieved strong revenue growth and is piloting exocad ART in select European markets, with broader rollout planned this year. Its strong lab presence enhances integration with iTero scanner and Invisalign. We expect this trend to have persisted in the first quarter as well.
The company’s growing suite of digital diagnostic tools, including Align Oral Health Suite and Align X-ray Insights, helps doctors identify conditions earlier and deliver clearer, more informed treatment recommendations. We expect all these tools to have positively impacted Align Technology’s revenues in the first quarter.
The Zacks Consensus Estimate for the segment’s revenues implies an increase of 2.3% on a year-over-year basis.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:
Earnings ESP: Align Technology has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1 at present. The company is expected to release first-quarter 2026 results soon.
AGEN’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 31.42%. The Zacks Consensus Estimate for first-quarter EPS implies an increase of 289.3% from the year-ago quarter’s figure.
Biogen (BIIB - Free Report) has an Earnings ESP of +3.26% and a Zacks Rank #2 at present. The company is slated to release first-quarter 2026 results soon.
BIIB’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 19.8%. The Zacks Consensus Estimate for first-quarter EPS implies a year-over-year decrease of 0.3%.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2 at present. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for first-quarter EPS suggests a 17.7% year-over-year improvement.